Open AccessDonor‐derived M2 macrophages attenuate GVHD after allogeneic hematopoietic stem cell transplantation
Author(s) -
Hanaki Ryo,
Toyoda Hidemi,
Iwamoto Shotaro,
Morimoto Mari,
Nakato Daisuke,
Ito Takahiro,
Niwa Kaori,
Amano Keishiro,
Hashizume Ryotaro,
Tawara Isao,
Hirayama Masahiro
Publication year - 2021
Publication title -
immunity, inflammation and disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 18
ISSN - 2050-4527
DOI - 10.1002/iid3.503
Subject(s) - immunology , hematopoietic stem cell transplantation , stem cell , macrophage , medicine , bone marrow , haematopoiesis , immune system , graft versus host disease , hematopoietic stem cell , t cell , transplantation , cancer research , in vitro , biology , microbiology and biotechnology , biochemistry
Graft‐versus‐host disease (GVHD) is frequent and fatal complication following allogeneic hematopoietic stem cell transplantation (HSCT) and characteristically involves skin, gut, and liver. Macrophages promote tissue regeneration and mediate immunomodulation. Macrophages are divided into two different phenotypes, classically activated M1 (pro‐inflammatory or immune‐reactive macrophages) and alternatively activated M2 (anti‐inflammatory or immune‐suppressive macrophages). The anti‐inflammatory effect of M2 macrophage led us to test its effect in the pathophysiology of GVHD. Methods GVHD was induced in lethally irradiated BALB/c mice. M2 macrophages derived from donor bone marrow (BM) were administered intravenously, while controls received donor BM‐mononuclear cells and splenocytes. Animals were monitored for clinical GVHD and analyzed. Results We confirmed that administering donor BM‐derived M2 macrophages attenuated GVHD severity and prolonged survival after HSCT. Moreover, donor BM‐derived M2 macrophages significantly suppressed donor T cell proliferation by cell‐to‐cell contact in vitro. Conclusions We showed the protective effects of donor‐derived M2 macrophages on GVHD and improved survival in a model of HSCT. Our data suggest that donor‐derived M2 macrophages offer the potential for cell‐based therapy to treat GVHD.